AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06513884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of matched placebo for HB-202 alternating with matched placebo for HB-201, with the first 2 treatment cycles administered every 3 weeks and then every 6 weeks from the third treatment cycle onwards.
Study NCT06555913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland Mobilization
Description: MM applies a passive oscillatory technique, classified from Grade I-IV with respect to intensity, to the shoulder in order to treat pain and stiffness.~Grade I refers to an intensity of small amplitude that is applied at the beginning of the joint ROM, where there is no loading on connective tissue; it is often used in cases of severe pain
Study NCT06555913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular Stabilization
Description: Scapular stabilization exercises are thought to have an important role in improving pain and dysfunction in the shoulder. The concept that an unstable~scapula is associated with pathology and dysfunction of the shoulder is well accepted. The predominant theory emphasizes that for optimal function of the glenohumeral joint, the scapula must provide a stable base upon which upper extremity tasks are completed. Impaired scapular stability increases the risk for pathologies such as impingement or rotator cuff tears
Study NCT06555913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy
Description: ROM exercises, stretching exercises and strengthening exercises for shoulder muscles
Study NCT06560853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive School Health Programme
Description: Combination intervention which consists of:~* Upgrading sanitation facilities and constructing a 'health room' in the school~* Health teacher training: 5-10 teachers per school are recruited and trained for two weeks to become School Health Workers (SHWs) by Healthy Learners~* The SHWs: (1) deliver education on health and good sanitation and hygiene (2) coordinate with local clinics to deliver preventive care (e.g. school deworming and vitamin A supplementation); (3) assess sick students in the health room with a tablet-based clinical decision support system (CDSS); (4) treat sick students in the health room for some conditions (malaria, diarrhoea, schistosomiasis, pneumonia, conjunctivitis) or (5) refer to the health facility for treatment; (6) monitor absence of learners~* Referral: learners referred by SHWs are given a referral form by the SHW, which contains information about symptoms and suggested diagnosis by the CDSS. The learners are prioritised in the local clinic.
Study NCT06560853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deworming and vitamin A supplementation delivery
Description: Schools implement the government policy of distributing deworming drugs and vitamin A supplementation to learners twice a year. Additional support from Healthy Learners ensures reliable delivery.
Study NCT06560853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deworming and vitamin A supplementation delivery
Description: Schools implement the government policy of distributing deworming drugs and vitamin A supplementation to learners twice a year. Additional support from Healthy Learners ensures reliable delivery.
Study NCT05895383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Description: Nitrous oxide administered at concentrations of minimal sedation (0-50%). Participants will be able to adjust the level of gas throughout the vasectomy using a handheld remote control.
Study NCT06513884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
Study NCT06306703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: group1, group2, group 3
Description: to teaching with verbal instruction to teaching with digital vaginal palpation to teaching with perineometer
Study NCT06302036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EFT
Description: EFT
Study NCT06513884 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous administration of pembrolizumab, with the first 2 treatment cycles administered at a dosage of 200 mg every 3 weeks and then every 6 weeks from the third treatment cycle onwards administered at a dosage of 400 mg.
Study NCT05792839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominoplasty with ventral hernia repair versus ventral hernioplasty.
Description: We do surgical treatment for ventral hernia in the form of hernioplasty with surgical mesh placement or by means of abdominoplasty surgical technique.
Study NCT06279039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exosome liquid dressing
Description: This study mainly adopted a randomized double-blind self-half face control method. The double-blind method was that the subjects and researchers did not know the experimental group and the control group. 38 sets of matched use sets (left and right, only the manufacturer knew the specific ingredients) were respectively applied to both sides of the cheeks of patients after Q-switched laser. The blind was unblinded after the experiment.
Study NCT04948905 — intervention group
Intervention type: OTHER
Intervention: Evaluation using the Self-Defining Memory Questionnaire
Description: This questionnaire consists of 3 pages. Page 1 gives a clear, concise definition of a memory that defines the self. This enlightens the subject on what is expected and helps him/her consider the phenomenological characteristics of the Self-Defining Memory. Page 2 recalls the 6 essential characteristics of the Self-Defining Memory. Page 3 allows the practical application of what has been understood about the questionnaire. At least 3 memories are asked of the participants. Each memory is rated as follows : On a scale of 0 - 6 for each of the following emotions, participants note how they feel when recalling each memory. Happy, Sad, Angry, Fearful, Surprised, Ashamed,Disgusted,Guilty, Interested, Embarrassed, Contemptful, Proud. 0 = not at all, 3 = Moderately and 6 = Extremely.~Participants must then use the same scale to indicate the vividness and importance of the memory.~They must also note the approximate number of years ago the memory took place (to the nearest whole number).
Study NCT05785611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily
Study NCT05912127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported fixed full arch prosthesis
Description: the patients will receive screw-retained cast metal-ceramic fixed prostheses that replace lost gingival tissues with pink porcelain.
Study NCT06131710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isolated Strengthening Exercises
Description: Isolated strengthening exercises can be beneficial for individuals with Patellofemoral Pain Syndrome (PFPS) to help address muscle imbalances and alleviate pain.
Study NCT06131710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Strengthening Exercises
Description: Combined strengthening exercises for Patellofemoral Pain Syndrome (PFPS) typically include a mix of quadriceps strengthening exercises, hip strengthening exercises, and core stability exercises. The goal is to address muscle imbalances and improve the overall stability of the knee joint.
Study NCT04927312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06947386
Description: Ceftazidime-Avibactam powder for concentrate for solution for infusion 2.0 g/ 0.5 g. Dosage will be adjusted based on renal function after enrollment.
Study NCT04927312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 0.5 g solution for injection.
Study NCT04986501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MucoPEG
Description: Experimental
Study NCT04986501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biotene
Description: Active Comparator
Study NCT05785611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets administered orally once daily
Study NCT04936321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT for Insomnia
Description: The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
Study NCT04936321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT for Pain Management
Description: The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
Study NCT04936321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered CBT for Pain Management
Description: The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
Study NCT04936321 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered Sleep Education
Description: The program delivers publicly available information about sleep.
Study NCT03883945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIV001
Description: intradermal injection
Study NCT03883945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: intradermal injection
Study NCT05064241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Access to Genetic Counselor for answering questions
Description: A genetic counselor answers questions posed by participants in the intervention arm on how to access genetic medicine. At the end of the study, the number of participants who were able to access genetic medicine will be assessed
Study NCT05841472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
Description: * 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles.
Study NCT04894799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular stimulation
Description: In Vestibular Stimulation (VS) group, all participants will be given Infant Swing activity for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Infant Swing for 30 minutes and frog swing for 30 minutes for two weeks. Next 7th and 8th weeks, Infant Swing (30 minutes) and prone on frog swing feet touching the floor (30 minutes), trice a day will be applied. In 9th week, Infant swing and normal playground swing for 30,30 minutes will be given to all participants, trice a day. In Last week of intervention i.e., 10th week, all participants will be given Infant Swing for 30 minutes and standing on platform swing (30 minutes) trice a day.
Study NCT04894799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck Control facilitation exercises
Description: all participants will be given Neck Control facilitation exercises using Bobath Approach of low tone facilitation method, for one hour, trice a day for first 4 weeks. After that, in 5th and 6th weeks, all participants will be given Neck Control facilitation exercises for 30 minutes and sitting facilitation Exercises with trunk weight shifting for 30 minutes, trice a day. Next 7th and 8th weeks, Neck Control facilitation exercises (30 minutes) and sitting facilitation exercises with trunk weight shifting and kneeling weight bearing (30 minutes), trice a day will be applied. In 9th and 10th weeks, Neck Control facilitation exercises, sitting and kneeling weight bearing and standing with trunk elongation will be given to all participants for one hour, trice a day.
Study NCT04937023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid gel
Description: Following scaling and root planing in intrabony defects UDCA gel will be injected
Study NCT04937023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic acid gel
Description: Following scaling and root planing in intrabony defects UDCA gel will be injected
Study NCT05280561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHM
Description: DHM is a positive modulator of GABA. We hypothesize the DHM could reduce stress/anxiety induced insomnia during the pandemic
Study NCT05280561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients including extracts of celery, strawberry, oranges, rose, and beet blended in powder form of 1 g
Study NCT05265650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BO-112 in combination with ablative radiotherapy (SABR) and nivolumab
Description: Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
Study NCT05265650 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue Biopsies
Description: Four research biopsies will be taken from accessible injected lesions, at the time of the IT injection of BO-112.
Study NCT05934448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab via iv, dosage and timing per protocol
Study NCT05934448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphodepletion Chemotherapy
Description: Participants will undergo lymphodepleting chemotherapy (fludarabine, cyclophosphamide) for CAR T-cell therapy as per SOC
Study NCT05934448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor (CAR) Therapy Infusion
Description: Day 0 in the hospital and will remain in the inpatient setting for observation for a minimum of 7 days or until CAR T-cell toxicities resolve to grade 1 or better. The choice of CAR-T product will be left to the discretion of the treating investigator.
Study NCT05934448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: manufacturing using commercial product as per standard of care (SOC) Cycle 1 Day -21 or earlier
Study NCT05693571 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Valera Smart Phone Application and Care Manager Dashboard
Description: Valera mobile health application will provide educational materials around mental health and Systemic Lupus Erythematosus (SLE) and the ability to connect to a SLE care team via a care manager.
Study NCT05742295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: Coadministration of vitamin K with the first dose of cefoperazone/sulbactam
Study NCT05074693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EASE app
Description: EASE is a mobile intervention designed to reduce ongoing mental health concerns among BLAI individuals with elevated anxiety and/or depressive symptoms by targeting anxiety sensitivity. The EASE app employs a variety of features to educate its users on how to deal with increased levels of stress, anxiety, and depression, and train users on how to better cope with the negative feelings of stress. The app contains a series of on-demand features, including a coping toolkit, stress management trainings, and a series of educational videos designed to teach participants how to better deal with stress. EASE also utilizes Ecological Momentary Assessments (EMAs) to gather information, and provide personalized messages to users in real time. Finally, EASE is outfitted with COVID-19 related elements, including a symptoms tracker (which participants can use to report symptoms of COVID-19 they may be experiencing), and a collection of COVID-19 related food, housing, and job placement resources.
Study NCT05074693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: INSIGHT (Control) App
Description: A standard of care control intervention was developed using the INSIGHT platform. This app contains a library of educational videos that cover topics such as meditation and mindfulness, as well as general stress reduction techniques. Additionally, participants have access to a Report Distress feature that enables them to report moments when they are feeling high levels of stress. Finally, participants will be able to report any COVID-19 related symptoms they experience using a COVID-19 symptom tracker feature. Participants assigned to this condition will received 2 daily EMAs, during which they will be prompted to watch one of the aforementioned educational videos.
Study NCT05260346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cranberry juice
Description: composition: Water, cranberry juice concentrate
Study NCT05260346 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: composition: Water, dextrose, citric acid, malic acid, fumaric acid, colorants, xanthan gum, natural flavor, emulsion
Study NCT06267404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iliopsoas Positional release therapy
Description: Group A(Iliopsoas Positional release group) Patient supine, with both hips are fully extended .Find a Tender point in Iliopsoas muscle, at the initiation of pain Passively try combination of flexion Adduction/Abduction medial or lateral rotation at hip joint and stop where pain start to diminished. Hold this position of relief for 30 seconds until minimum of 75% of relief is achieved. Apply three times, than passively take lower limb in extension. Administered on both limbs.
Study NCT05504382 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: naproxen phonophoresis
Description: transmission of naproxen molecule by therapeutic ultrasound
Study NCT05585190 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention.
Study NCT05585190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2-Hour Stand Group
Description: Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 2 hours each work day.
Study NCT05585190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-Hour Stand Group
Description: Subjects will also receive a weekly email/text reminding them to maintain the desk in the standing position at LEAST 3 hours each work day.
Study NCT06267404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercises
Description: Group B (conventional Physical therapy) For Ultra sonic therapy Patient prone lying, Aqua-sonic gel is applied to lumbosacral area and ultrasonic head is moved in circular motion. For TENS Electrodes are placed in crossed pattern, Paravertebral at L1 and L5 (Box Pattern)with circuit crossing at L3 and current is applied for 10 minutes, Hot pack which is kept in hydro-collateral at 70°C and 75°C is, wrapped in several towel layers, applied for 10 minutes.
Study NCT05350423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thulium Fibre Laser
Description: The TFL is a relatively new laser in the field of urology. First introduced on the market in 2017, it offers theoretically superior stone dusting qualities and smaller fiber sizes to allow for better irrigation.
Study NCT05350423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium:Yttrium-Aluminum-Garnet
Description: The Ho:YAG is currently the most commonly used laser in the field of urology and for the better part of the last 3 decades has been considered the gold standard for laser lithotripsy.
Study NCT05499936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: 68Ga-FAPI were injected into the patients before the PET/CT scans
Study NCT05683522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-omohyoidal Plane Block
Description: The ultrasound guided sub-omohyoidal plane block will be performed. Patients in this group will be given 15 mL of local anesthetic into the interfascial plane under the omohyoid muscle. This block will be performed preoperatively.
Study NCT05683522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical Plexus Block
Description: A cervical plexus block will be applied by applying 10 mL of local anesthetic under ultrasound guidance. This block will be done before the surgery.
Study NCT05683522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Costoclavicular Block
Description: Costoclavicular brachial plexus block will be applied by administering 20 mL of local anesthetic under ultrasound guidance. This block will be performed preoperatively.
Study NCT06139263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a percussion massage gun (Compex Fix 2.0)
Description: Vibration application will be applied to the individuals in this group in addition to conventional methods. Vibration application will be applied to the trapezius, levator scapula and cervical paravertebral muscles with a percussion massage gun (Compex Fix 2.0) along the origo-insersio line for 3 minutes for each muscle group. Vibration application will be made with the soft head of the percussion massage gun. Vibration therapy will be applied 3 days a week for 3 weeks.